A Cure in Sight: Who We Are

Melody Burchett discusses her journey with uveal melanoma and the formation of A Cure in Sight. This program was made possible with support from Immunocore.

EP: 1.Brief Overview of Uveal Melanoma

Now Viewing

EP: 2.A Cure in Sight: Who We Are

EP: 3.Diagnosing Uveal Melanoma

EP: 4.Resources for Patients With Newly Diagnosed Uveal Melanoma

EP: 5.Uveal Melanoma Prognosis and Risk Stratification

EP: 6.Choosing the Appropriate Treatment for Metastatic Uveal Melanoma

EP: 7.Safety and Efficacy of Tebentafusp

EP: 8.Unmet Needs and Challenges in Metastatic Uveal Melanoma

Video content above is prompted by the following:

• What is the focus of your organization, A Cure in Sight?

Related Videos

Related Content

Advertisement

November 12th 2024

Managing Trodelvy’s Side Effects Through Dose Adjustment

Spencer Feldman

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.

Related Content

Advertisement

November 12th 2024

Managing Trodelvy’s Side Effects Through Dose Adjustment

Spencer Feldman

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.